Objectives: This study is aimed; to assess the knowledge, awareness and attitude of pharmacists in the community and hospital settings towards pharmacogenetic, to understand the differences of knowledge, awareness and attitude between community and hospital settings and to understand the factors predict the knowledge, awareness and attitude of the pharmacists.
Methods:We conducted a cross-sectional study over 60 community pharmacies and 11 clinics and hospital pharmacies. We recruited 84 hospital pharmacists in the private hospitals and 24 community pharmacists. The questionnaire about knowledge, awareness and attitude of pharmacists towards pharmacogenetic were adopted from previous study. We also collected the data of demographic by interviewing the respondents.
Results:Our study finds the significant differences of attitude between community and hospital pharmacists. The scores of knowledge, awareness and attitude in community setting are higher than the score of those in hospital settings. In the hospital setting, only education and CPD which may predict the awareness of pharmacists. In the community setting, characteristics which may predict the knowledge, awareness and attitude are outpatient services, work duration and CPD, respectively (p<0.05).
Conclusion:The knowledge and awareness of pharmacists toward pharmacogenetic in Yogyakarta are good. Pharmacists' characteristics that may predict the knowledge, awareness and attitude toward pharmacogenetic are education, internal CPD, work duration, and types of patient's service.
This study was aimed to understand differences of ondansetron serum concentration in each antiemetic responses, polymorphisms of 5HT3B receptor, CYP2D6 and ABCB1 genes in Indonesian cancer patients treated with high emetogenic cytostatics. We recruited cancer patients in Dr Sardjito Hospital treated with cisplatin (≥ 50 mg/m 2 ) as monotherapy or combination therapy. Patients were treated with ondansetron 8 mg intravenously and dexamethasone 8 mg intravenously and metoclopramide (10 mg orally) after cytostatic administration until 5 days after chemotherapy. We cathegorized the nausea and vomiting grade according to the National Cancer Institute Common Toxicity Criteria v.3. We also determined some SNPs of ABCB1, 5HT3B and CYP2D6 genes using realtime PCR. We recruited 191 cancer patients in this study with the average of ondansetron serum concentration reached 33.48 ng/ml (SD: 18.54). According to the patients' response to the antiemetic, during the acute phase, 21.8% patients experienced acute nausea and 30.2% patients experienced acute vomiting. Only the haplotype of CTG-CTG of ABCB1 which have significant association with ondansetron serum concentration. EM patients of CYP2D6 and patients with haplotype of delAG of 5HT3B had lower ondansetron serum concentration. However, IM patients of CYP2D6 showed higher ondansetron serum concentration and lower grade of nausea and vomiting. Variations of ABCB1, CYP2D6 and 5HT3B may be used as pharmacogenetic marker in predicting antiemetic response in cancer patients receiving highly emetogenic cytostatic.
ABSTRAKPenelitian ini bertujuan untuk mengetahui perbedaan konsentrasi ondansetron serum dalam setiap respon antiemetik, polimorfisme gen reseptor 5HT3B , CYP2D6 dan ABCB1 pada pasien kanker yang mendapatkan sitostatika emetogenik tinggi di Indonesia. Subjek dalam penelitian ini adalah pasien kanker di RSUP Dr Sarjito Hospital yang mendapatkan terapi sisplatin (≥ 50 mg/m 2 ) baik sebagai terapi tunggal maupun kombinasi. Subjek mendapatkan terapi ondansetron 8 mg, iv dan deksametason 8 mg, dan metoklopramid setelah pemberian sitostatika sampai hari kelima kemoterapi. Kategori mual muntah berdasarkan National Cancer Institute Common Toxicity Criteria v.3. Beberapa SNPs pada
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.